Outcomes of Talimogene Laherparepvec in Soft Tissue Sarcoma

Talimogene laherparepvec (T-VEC), an intralesional therapy designed to elicit an immunogenic anti-tumor response, has a favorable safety profile in phase II trial and may be an effective second-line therapeutic in sarcoma; however, there is a paucity of data on its therapeutic efficacy. We present a case series of patients who received T-VEC for sarcoma at a high-volume sarcoma center. A total of four patients who had prior progression of disease on immune checkpoint inhibitors (ICI) received a median of 9.5 (range, 4-15) doses of T-VEC over 26.5 (range, 10-49) weeks with a median progression free-survival of 9 weeks (range, 9-10). Only one patient experienced toxicity, which presented as mild flu-like symptoms. This case series of patients receiving T-VEC for sarcoma adds to the literature of intralesional therapies for this rare disease. Our experience suggests that T-VEC may be administered safely and may provide local tumor control in select patients with sarcoma who have failed prior therapy with ICI.